Evaluation of Topical ATR12-351 in Adults With Netherton Syndrome

Summary

The objectives of this clinical trial are to evaluate the safety and tolerability of topically applied ATR12-351, to understand what the body does to ATR12-351, and to observe treatment benefits of the drug in approximately 12 adult patients with Netherton Syndrome (NS). ATR12-351 will be applied to skin lesions on one side of the body, while the vehicle control will be applied to similar lesion on the other side of the body twice daily for 2 weeks.

Timeline

Start

2024-06-19

Primary completion

2026-06-01

Completion

2026-08-01

Drugs

Indications